Previous studies demonstrate that gliomas with deletion at both 1p and 19q and gliomas with EGFR amplifications are mutually exclusive regarding their cell(s) of origin, profiles of transcriptomic and genomic alterations, and clinical characteristics [45], [46], [47], [48], [49], [50]. Here, EGFR is linked to central nervous system cancer.